Crossmark

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports

Crossref DOI link: https://doi.org/10.1186/s13052-019-0736-5

Published Online: 2019-11-09

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cutrera, Renato

Wolfler, Andrea

Picone, Simonetta

Rossi, Giovanni A.

Gualberti, Giuliana

Merolla, Rocco

Del Vecchio, Antonio

Villani, Alberto

Midulla, Fabio

Dotta, Andrea
Funding

Funding for this research was provided by:

AbbVie srl (No grant number)
License Information

Text and Data Mining valid from 2019-11-09

Version of Record valid from 2019-11-09
More Information

Article History

Received: 30 August 2019

Accepted: 15 October 2019

First Online: 9 November 2019

Ethics approval and consent to participate

: This review is based on published papers, posters and abstracts and therefore did not call for any further ethical approval.

: Not applicable.

: R Cutrera declares conflicts of interests with AbbVie.G Rossi declares conflicts of interests with AbbVie, Lusofarmaco, ViforPharma, Chiesi.A Villani declares conflicts of interests with Abbvie, Glaxo, MSD, Pfizer, Sanofi.G Gualberti and R Merolla are employees of AbbVie and may own AbbVie stocks / options.A Del Vecchio, F Midulla, A Dotta, S Picone and A Wolfler declare no conflicts of interests.

Document is current

Any future updates will be listed below